A startup company from Keio University School of Medicine and Nagoya Institute of Technology, developing a visual restoration gene therapy using AAV (adeno-associated virus) vectors with the unique function gene “Chimeric Rhodopsin” to treat blindness.
Our core technology is “Chimeric Rhodopsin” and we’ll develop a visual restoration gene therapy with the AAV vector for retinitis pigmentosa. Our therapy will enable the blind patients to see even under low light conditions without goggles. It has proven to have competitive advantages at the pre-clinical stage.
Voice from Acceralator
Pre-Clinical, 2016 Restore Vision is a startup from Keio University School of Medicine. Restore Vision is developing gene therapy to restore vision for blind patients with retinitis pigmentosa. Retinitis pigmentosa is a designated intractable disease with no current treatment. Restore Vision is developing a gene therapy for visual restoration using chimeric rhodopsin, a light-sensing protein. Their product delivers genes with an AAV vector, causes chimeric rhodopsin gene induction, and enables patients to see even under low light conditions without goggles.